Guselkumab - In Psoriasis and Beyond
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where gus...
| Published in: | Dermatology Practical & Conceptual |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2024-07-01
|
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/4176 |